<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063749</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16025RES003</org_study_id>
    <nct_id>NCT03063749</nct_id>
  </id_info>
  <brief_title>RESOLUTE ONYX Post-Approval Study</brief_title>
  <acronym>ONYX PAS</acronym>
  <official_title>A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting
      Coronary Stent System in a real-world more-comer population.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure</measure>
    <time_frame>12 months</time_frame>
    <description>Target Lesion Failure (TLF), defined as cardiac death, target vessel myocardial infarction (Q wave and non-Q wave), or clinically driven target lesion revascularization (TLR) by percutaneous or surgical methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Success (Device, Lesion, Procedure)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Acute Success (Device, Lesion, Procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Cardiac Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Myocardial Infarction (TVMI)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Target Vessel Myocardial Infarction (TVMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death and TVMI</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Cardiac Death and TVMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Defined as death, myocardial infarction (Q wave and non-Q wave), emergent coronary bypass surgery, or clinically-driven repeat target lesion revascularization by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Target Lesion Failure (TLF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Target Vessel Failure (TVF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis (ST)</measure>
    <time_frame>30 days and 6, 12, 24, and 36 months post-procedure</time_frame>
    <description>Stent Thrombosis (ST)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">510</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Primary Cohort</arm_group_label>
    <description>Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extra Large Vessel (XLV) Cohort.</arm_group_label>
    <description>Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</intervention_name>
    <description>Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm</description>
    <arm_group_label>Primary Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System</intervention_name>
    <description>Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm</description>
    <arm_group_label>Extra Large Vessel (XLV) Cohort.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The device will be used in subjects meeting the inclusion and exclusion criteria according
        to the Instructions for Use.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          -  Symptomatic coronary artery disease including subjects with chronic stable angina,
             silent ischemia, and acute coronary syndromes including non-ST elevation and
             ST-elevation myocardial infarction

          -  Subject is an acceptable candidate for treatment with a drug eluting stent in
             accordance with the applicable guidelines on percutaneous coronary interventions,
             manufacturer's Instructions for Use, and the Declaration of Helsinki

        Key Exclusion Criteria

          -  Unprotected left main disease

          -  Subjects with planned PCI of three vessel disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg - Campus Sint-Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>February 21, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
